Results 11 to 20 of about 612,123 (266)
Molecular targeted therapy for anticancer treatment. [PDF]
AbstractSince the initial clinical approval in the late 1990s and remarkable anticancer effects for certain types of cancer, molecular targeted therapy utilizing small molecule agents or therapeutic monoclonal antibodies acting as signal transduction inhibitors has served as a fundamental backbone in precision medicine for cancer treatment.
Min HY, Lee HY.
europepmc +3 more sources
Molecular Targets for AIDS Therapy [PDF]
The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro.
Mitsuya, H., Yarchoan, R., Broder, S.
openaire +3 more sources
Molecular targeted therapy of glioblastoma [PDF]
Glioblastomas are intrinsic brain tumors thought to originate from neuroglial stem or progenitor cells. More than 90% of glioblastomas are isocitrate dehydrogenase (IDH)-wildtype tumors. Incidence increases with age, males are more often affected. Beyond rare instances of genetic predisposition and irradiation exposure, there are no known glioblastoma ...
Le Rhun, Emilie +7 more
openaire +4 more sources
Targeted Molecular Therapies for SBMA [PDF]
Spinal and bulbar muscular atrophy (SBMA) is a late-onset neuromuscular disease caused by a polyglutamine expansion in the androgen receptor gene which results in progressive spinal and bulbar motor neuron degeneration, and muscle atrophy. Although the causative genetic defect is known, until recently, the molecular pathogenesis of the disease was ...
Rinaldi, C, Malik, B, Greensmith, L
openaire +3 more sources
Molecular imaging and targeted therapies [PDF]
Targeted therapeutic and imaging agents are becoming more prevalent, and are used to treat increasingly smaller segments of the patient population. This has lead to dramatic increases in the costs for clinical trials. Biomarkers have great potential to reduce the numbers of patients needed to test novel targeted agents by predicting or identifying non ...
David L, Morse, Robert J, Gillies
openaire +2 more sources
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer
Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels. Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in approximately 40% of all CRC cases; its mutations result in constitutive ...
Gongmin Zhu +4 more
doaj +1 more source
Targeted Molecular Therapy of GBM
Major advances in molecular biology, cellular biology and genomics have substantially improved our understanding of cancer. Now, these advances are being translated into therapy. Targeted therapy directed at specific molecular alterations is already creating a shift in the treatment of cancer patients.
Paul S, Mischel, Timothy F, Cloughesy
openaire +3 more sources
A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
In recent years, as our understanding of tumor immunology is continuously improved, immunotherapy has come to the center stage of cancer therapy and is deemed as the most promising approach for cancer control.
Qian Huang +4 more
doaj +1 more source
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia +6 more
doaj +1 more source
Encoded by the MEN1 gene, menin protein is a fusion protein that is essential for the oncogenic transformation of mixed-lineage leukemia (MLL) and leads to acute leukemia (AL). Therefore, accumulating evidence has demonstrated that inhibition of the high-
Qing Shi +4 more
doaj +1 more source

